Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103.

Purpose Racial disparity in breast cancer outcomes exists between African American and Caucasian women in the United States. We have evaluated the impact of genetically determined ancestry on disparity in efficacy and therapy-induced toxicity for breast cancer patients in the context of a randomized, phase III adjuvant trial. Patients and Methods This study compared outcomes between 386 patients of African ancestry (AA) and 2473 patients of European ancestry (EA) in a randomized, phase III breast cancer trial; ECOG-ACRIN-E5103. The primary efficacy endpoint, invasive disease free survival (DFS) and clinically significant toxicities were compared including: anthracycline-induced congestive heart failure (CHF), taxane-induced peripheral neuropathy (TIPN), and bevacizumab-induced hypertension. Results Overall, AAs had significantly inferior DFS (p=0.002; HR=1.5) compared with EAs. This was significant in the estrogen receptor-positive subgroup (p=0.03); with a similar, non-significant trend for those who had triple negative breast cancer (TNBC; p=0.12). AAs also had significantly more grade 3-4 TIPN (OR=2.9; p=2.4 ×10-11) and grade 3-4 bevacizumab-induced hypertension (OR=1.6; p=0.02), with a trend for more CHF (OR=1.8; p=0.08). AAs had significantly more dose reductions for paclitaxel (p=6.6 ×10-6). In AAs, dose reductions in paclitaxel had a significant negative impact on DFS (p=0.03); whereas in EAs, dose reductions did not impact outcome (p=0.35). Conclusion AAs had inferior DFS with more clinically important toxicities in ECOG-ACRIN-E5103. The altered risk to benefit ratio for adjuvant breast cancer chemotherapy should lead to additional research with the focus centered on the impact of genetic ancestry on both efficacy and toxicity. Strategies to minimize dose reductions for paclitaxel, especially due to TIPN, are warranted for this population.

[1]  W. Darity,et al.  Self-identified race, socially assigned skin tone, and adult physiological dysregulation: Assessing multiple dimensions of “race” in health disparities research☆ , 2016, SSM - population health.

[2]  Lang Li,et al.  Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. , 2016, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  L. Pusztai,et al.  Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Ross,et al.  Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Daniel L. Koller,et al.  Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199 , 2015, Clinical Cancer Research.

[6]  L. Carey,et al.  Race, response to chemotherapy, and outcome within clinical breast cancer subtypes , 2015, Breast Cancer Research and Treatment.

[7]  David Reich,et al.  The Genetic Ancestry of African Americans, Latinos, and European Americans across the United States , 2015, American journal of human genetics.

[8]  Tesfaye B Mersha,et al.  Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities , 2015, Human Genomics.

[9]  Daniel L. Koller,et al.  Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100 , 2014, British Journal of Cancer.

[10]  Saranya Chumsri,et al.  Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience , 2014, SpringerPlus.

[11]  O. Lao,et al.  The impact of self-reported ethnicity versus genetic ancestry on phenotypic characteristics of polycystic ovary syndrome (PCOS). , 2014, The Journal of clinical endocrinology and metabolism.

[12]  W. Gradishar,et al.  Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. , 2014 .

[13]  Jeffrey H Silber,et al.  Characteristics associated with differences in survival among black and white women with breast cancer. , 2013, JAMA.

[14]  E. Perez,et al.  Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. , 2012, Journal of the National Cancer Institute.

[15]  Lili Ding,et al.  Comparison of measures of marker informativeness for ancestry and admixture mapping , 2011, BMC Genomics.

[16]  A. Jemal,et al.  Disparities in breast cancer prognostic factors by race, insurance status, and education , 2010, Cancer Causes & Control.

[17]  Melissa A. Basford,et al.  Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. , 2010, American journal of human genetics.

[18]  Dawn L Hershman,et al.  Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. , 2009, Journal of the National Cancer Institute.

[19]  Gabriel Silva,et al.  Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America , 2009, Human mutation.

[20]  Mark Shriver,et al.  A panel of ancestry informative markers for estimating individual biogeographical ancestry and admixture from four continents: utility and applications , 2008, Human mutation.

[21]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[22]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[23]  T. Sellers,et al.  Examining Population Stratification via Individual Ancestry Estimates versus Self-Reported Race , 2005, Cancer Epidemiology Biomarkers & Prevention.

[24]  L. Jorde,et al.  Genetic variation, classification and 'race' , 2004, Nature Genetics.

[25]  J. Kark,et al.  Doxorubicin cardiotoxicity in African Americans. , 2004, Journal of the National Medical Association.

[26]  K. Weiss,et al.  Race, ancestry, and genes: implications for defining disease risk. , 2003, Annual review of genomics and human genetics.

[27]  J. Goldstein,et al.  Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. , 2001, Pharmacogenetics.

[28]  J. Krischer,et al.  Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Falk,et al.  Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. , 1997, Kidney international.